Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

Novo Nordisk's experimental heart medicine ziltivekimab has failed a clinical trial. According to CNBC, the drug did not achieve statistically significant improvements in major cardiovascular events, marking another setback for the pharmaceutical company's development pipeline.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton